July 23, 2014
Mycobacteria Metabolism Discovery Could Pave Way For New Tuberculosis Drugs
The mystery of why mycobacteria—a family that includes the microbe that causes TB—are extraordinarily hardy organisms is being unraveled by University of Otago, New Zealand, research that offers new hope for developing a revolutionary class of antibiotics to tackle TB.In collaboration with researchers in the US and Germany, Otago microbiologists have teased out the mechanisms by which the aerobic soil microbe Mycobacterium smegmatis is able to persist for extreme lengths of time in the absence, or near-absence, of oxygen.
Their findings, published this week in the prestigious US journal PNAS, show that hydrogen is a key factor that enables mycobacteria to survive oxygen-limitation over long periods.
The team, led by Professor Greg Cook, found that in such conditions the bacterium is able to quickly switch its cellular metabolism from a primarily oxygen-based one over to one that uses fermentation for energy production instead.
This metabolic mode depends on the production and recycling of molecular hydrogen, a high-energy fuel and diffusible gas. These cells produce hydrogen to ensure their survival until they once more have access to sufficient oxygen for growth.
Professor Cook says it had long been a puzzle how mycobacteria generate energy when in their oxygen-starved dormant states.
"Mycobacteria grow through combusting their preferred carbon-based fuel sources using oxygen. However, they can also somehow survive for months or years when their oxygen supply is exhausted.
"For example, in people with latent TB infections, Mycobacterium tuberculosis bacteria are walled in by clumps of immune and other body cells in what is thought to be an extremely low oxygen environment. However, such patients must be monitored for the rest of their lives in case the bacteria become active again," he says.
Professor Cook's team have established that Mycobacterium smegmatis metabolizes molecular hydrogen using three enzymes called hydrogenases. One hydrogenase produces hydrogen, whereas the other two consume it. These hydrogenases are activated under oxygen starvation by a master regulator called DosR.
The researchers found that strains of Mycobacterium smegmatis in which the genes for the hydrogenases or the regulator DosR had been 'knocked out' experienced a hundredfold reduction in the long-term survival compared to the normal bacterium, he says.
His team is currently testing whether these findings are extendable to Mycobacterium tuberculosis, which activates a further predicted hydrogenase under low oxygen conditions.
"If knocking out this other hydrogenase also drastically reduces long-term survival, the enzyme might end up being an excellent next-generation drug target in latent TB infections, which around one-third of the world's population suffer."
The Otago researchers' studies on hydrogen fermentation in mycobacteria have been performed in collaboration with Professor William Jacobs Jr., a world-leading bacterial geneticist at the Albert Einstein College of Medicine in New York, who is known as the 'TB terminator'.
One of the paper's lead authors is Dr Michael Berney, a former research fellow in Professor Cook's laboratory who is now an Assistant Professor associated with Professor Jacobs' laboratory. The other co-authors include Professor Cook, Dr Chris Greening, who also co-led the study and recently completed his PhD studies in the Cook Laboratory, and Professor Dr Ralf Conrad, director of the Max-Planck Institute for Terrestrial Microbiology in Marburg, Germany.
The research was funded by the Royal Society of New Zealand's Marsden Fund.